| By Fraiser Kansteiner An approval in patients with preserved ejection fraction would help set Eli Lilly and Boehringer Ingelheim's Jardiance apart in a field where AstraZeneca’s Farxiga, Novartis' Entresto and Merck and Bayer’s Verquvo are already jockeying for space. And some data presented Friday at ESC could get it there. read more |
| |
|---|
|
| By Conor Hale Both minimally invasive devices are designed to reduce the long-term risk of stroke in patients with atrial fibrillation. read more |
| |
|---|
|
| By Kevin Dunleavy The European Society of Cardiology issued new guidelines for heart failure, recommending SGLT2s such as AstraZeneca's Farxiga for first-line treatment. Later, AZ presented data showing Farxiga's kidney benefits in patients with and without heart failure. read more |
| |
|---|
|
| By Kevin Dunleavy Bayer's chronic kidney disease drug Kerendia totted up kidney and cardiovascular outcomes wins in two massive trials at the European Society of Cardiology Congress on Saturday. While its efficacy figures fall short of rivals such as AstraZeneca’s Farxiga and Johnson & Johnson’s Invokana, Bayer believes Kerendia can add its own benefits. read more |
| |
|---|
|
| By Conor Hale A real-world study of Medtronic’s leadless pacemaker showed it led to fewer complications—with fewer patients having to return to the operating room—compared to wired cardiac implants over a period of two years. read more |
| |
|---|
|
| By Eric Sagonowsky While much of the attention at the European Society of Cardiology is expected to center on forthcoming heart failure data for Eli Lilly and Boehringer Ingelheim’s Jardiance, Lexicon Pharmaceuticals thinks it has a winner in the dual SGLT1 and SGLT2 inhibitor sotagliflozin. read more |
| |
|---|
|
| By Conor Hale In what they describe as the world’s first real-world feasibility study of drone-based defibrillator deliveries, first responders showed that going airborne helped shave off minutes where time matters most. read more |
| |
|---|
|
| By Kevin Dunleavy Bayer and Merck & Co. argue their new heart failure drug Verquvo has a role to play as an add-on to other treatments, such as Novartis' Entresto. And some data presented Saturday at the European Society Cardiology Congress could help prove their case. read more |
| |
|---|
|
| By Angus Liu Amarin has shored up data to back the use of its fish oil-derived Vascepa to protect against additional heart problems in patients who already had a heart attack. It comes as the company is trying to fend off Hikma's generic version with a "skinny label" suit. read more |
| |
|---|
|
|
|
